Ewart de Bruijn
Papers
1
Total Citations
86
H-Index
1
About
Ewart de Bruijn is a leading figure in the field of cancer genomics, with a primary focus on the clinical translation of whole genome sequencing (WGS) for oncology diagnostics. His most impactful work centers on demonstrating the feasibility and superiority of using WGS as a comprehensive, single-test alternative to traditional multi-biomarker assays. In his landmark 2021 study, which has garnered 86 citations, de Bruijn provided critical clinical validation for applying WGS to fresh-frozen tumor tissue and matched blood samples. This work directly addresses the pressing need for a more complete genetic tumor test, especially given the increasing prevalence of small biopsies and the growing number of actionable biomarkers. By advocating for an all-inclusive genomic approach, de Bruijn’s contributions are helping to streamline cancer diagnostics, reduce turnaround times, and improve the detection of clinically relevant mutations. His research is pivotal for moving precision oncology toward more efficient, cost-effective, and comprehensive testing paradigms, solidifying his reputation as a key translator of genomic technology into routine clinical practice.
Research Focus
Key Achievements
Top Papers
- 1Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics86 citations · 2021